source
- AstraZeneca's oral relaxin agonist shows positive phase 2b results in chronic heart failureAstraZeneca presented phase 2b data from its Luminara trial at the European Society of Cardiology Congress in Munich. The study evaluated the oral relaxin agonist AZD5462 in patients with chronic h…
- Personalized mRNA melanoma vaccine shows clinical success, reviving optimism for the platformModerna and Merck reported positive results from a personalized mRNA vaccine designed to treat melanoma in a recent clinical study. The outcome is being hailed as a boost for mRNA technology, whic…